Currently, a positive amyloid status, apolipoprotein E4 (ApoE4) carrier status, and elevated brain Abeta are risk factors for AD [5–7] and are inclusion criteria in clinical trial designs [8–10]. Here, APOE is linked to Alzheimer disease.